Antiviral Res. 2013 Dec;100(3):654-61. doi: 10.1016/j.antiviral.2013.10.009.
In previous studies we identified the interferon stimulated gene 15 (ISG15) as a pro-viral host factor in the pathogenesis of hepatitis C virus (HCV) infection. However, the functional link between ISG15 and the HCV replication cycle is not well understood. Aim of the present study was to functionally analyze the role of ISG15 and to identify possible HCV promoting effector molecules. Isg15 suppression was investigated in the murine subgenomic HCV replicon (MH1) transfected with Isg15-specific siRNA and in C57BL/6 mice intravenously injected with lipid nanoparticles (LNP)-formulated siRNA. Interestingly, the LNP-formulated siRNA led to hepatocyte-specific knockdown of Isg15 in vivo, which mediated a hypo-responsiveness to endogenous and exogenous interferon. A label free proteome analysis accompanied by western blot and quantitative RT-PCR techniques led to identification of five candidate proteins (Heterogeneous nuclear ribonucleoprotein A3 (HnrnpA3), Heterogeneous nuclear ribonucleoprotein K (HnrnpK), Hydroxymethylglutaryl-CoA synthase (Hmgcs1), Isocitrate dehydrogenase cytoplasmic (Idh1) and Thioredoxin domain-containing protein 5 (Txndc5)) that are either involved in lipid metabolism or belong to the family of Heterogeneous nuclear ribonucleoprotein (Hnrnp). All candidate proteins are likely to be associated with the HCV replication complex. Furthermore treatment with HnrnpK-specific siRNA directly suppressed HCV replication in vitro. Taken together these data suggest that targeting Isg15 may represent an attractive novel therapeutic option for the treatment of chronic HCV infection.
在之前的研究中,我们发现干扰素刺激基因 15(ISG15)是丙型肝炎病毒(HCV)感染发病机制中的一种促病毒宿主因子。然而,ISG15 与 HCV 复制周期之间的功能联系尚不清楚。本研究的目的是对 ISG15 的功能进行分析,并确定可能的 HCV 促进效应分子。通过用 ISG15 特异性 siRNA 转染的小鼠亚基因组 HCV 复制子(MH1)和用脂质纳米粒(LNP)配方 siRNA 静脉内注射的 C57BL/6 小鼠来研究 Isg15 的抑制作用。有趣的是,LNP 配方的 siRNA 导致体内肝细胞特异性敲低 Isg15,这介导了对内源性和外源性干扰素的低反应性。无标记的蛋白质组分析,结合 Western blot 和定量 RT-PCR 技术,鉴定出 5 种候选蛋白(异质核核糖核蛋白 A3(HnrnpA3)、异质核核糖核蛋白 K(HnrnpK)、羟甲基戊二酰辅酶 A 合酶(Hmgcs1)、细胞质异柠檬酸脱氢酶(Idh1)和硫氧还蛋白结构域蛋白 5(Txndc5)),它们要么参与脂质代谢,要么属于异质核核糖核蛋白(Hnrnp)家族。所有候选蛋白都可能与 HCV 复制复合物有关。此外,用 HnrnpK 特异性 siRNA 处理可直接抑制 HCV 在体外的复制。综上所述,这些数据表明,针对 ISG15 可能是治疗慢性 HCV 感染的一种有吸引力的新治疗选择。